Also known as: Body Protection Compound 157 · PL 14736 · Bepecin
BPC-157 is a synthetic pentadecapeptide (15 amino acids) isolated from human gastric juice protein BPC. It demonstrates broad regenerative properties across multiple tissue types including tendons, ligaments, muscle, bone, and the GI tract.
BPC-157 (Body Protective Compound-157) is one of the most extensively studied regenerative peptides. Discovered in and isolated from human gastric juice, it is a partial sequence of a larger protein found naturally in the gastric lining.
Its remarkable ability to accelerate healing across diverse tissue types has made it a subject of significant research interest. Unlike many research peptides, BPC-157 demonstrates systemic effects when administered via multiple routes — subcutaneous, intramuscular, or orally — with oral administration being particularly noteworthy as the gastric environment does not degrade the compound.
One of BPC-157's primary mechanisms involves upregulation of nitric oxide (NO) synthesis. NO acts as a potent vasodilator, improving local blood flow to injury sites and accelerating delivery of oxygen and repair factors.
BPC-157 upregulates VEGF (Vascular Endothelial Growth Factor) and EGF, promoting angiogenesis — the formation of new blood vessels essential for tissue repair.
The peptide directly activates tendon fibroblasts and promotes their migration to injury sites. It also upregulates the expression of Egr-1, a key transcription factor in tendon healing.
BPC-157 is derived from a naturally occurring protein in gastric juice and has an exceptional safety profile in animal models across hundreds of studies. No human clinical trials have been completed to date. Sourced as lyophilized powder — always verify purity via third-party CoA before use.
Many researchers run shorter acute courses of 2–4 weeks targeted at a specific injury and discontinue once healed. For systemic or gut-related uses, 4–6 week cycles are common. The off-cycle period allows assessment of lasting effects and prevents receptor adaptation.
Despite extensive preclinical evidence, BPC-157 lacks formal human clinical trials. This is largely because it is a naturally-derived compound and thus not easily patentable, reducing pharmaceutical development incentive. The FDA has not approved BPC-157 for human therapeutic use.
Ask anything about BPC-157 — mechanisms, dosing protocols, interactions, or research comparisons.
CJC-1295 without DAC (Modified GRF 1-29) is a GHRH analogue with four stabilising amino acid substitutions that extend i…
TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found in virtually a…
IGF-1 LR3 is a synthetic analog of Insulin-like Growth Factor 1 (IGF-1) with a 13-amino-acid N-terminal extension and a…
Ipamorelin is a selective pentapeptide growth hormone releasing peptide (GHRP) that stimulates pituitary GH release with…